These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16923585)

  • 1. Thyroid gland plasmacytoma with a dramatic and persistent complete response under thalidomide and dexamethasone-associated treatment.
    Terrier B; Aouba A; Diop S; Clerc J; Vasiliu V; Munera Y; Hermine O
    Leuk Lymphoma; 2006 Jul; 47(7):1424-6. PubMed ID: 16923585
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
    del Giglio A; Weinschenker P; Manhani AR; Carbonell AL; Mitteldorf CA
    South Med J; 2005 Feb; 98(2):238-40. PubMed ID: 15759959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature.
    Naymagon L; Abdul-Hay M
    J Med Case Rep; 2019 May; 13(1):153. PubMed ID: 31113466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
    Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
    Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.
    Bladé J; Perales M; Rosiñol L; Tuset M; Montoto S; Esteve J; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E
    Br J Haematol; 2001 May; 113(2):422-4. PubMed ID: 11380408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma.
    Hashimoto S; Kuroha T; Yano T; Sato N; Furukawa T
    Intern Med; 2016; 55(20):3025-3028. PubMed ID: 27746443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
    Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
    Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A smoldering/indolent myeloma with extensive abdominal presentation--case report.
    Omoti CE; Enosolease ME
    Niger J Clin Pract; 2006 Jun; 9(1):91-3. PubMed ID: 16986300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
    Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
    Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
    Wasser K; Moehler T; Neben K; Nosas S; Heiss J; Goldschmidt H; Hillengass J; Düber C; Kauczor HU; Delorme S
    Rofo; 2004 Sep; 176(9):1285-95. PubMed ID: 15346264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment.
    Watanabe N; Kitahara H; Iwao N; Ohta Y; Koike M; Komatsu N
    Geriatr Gerontol Int; 2018 Jun; 18(6):977-979. PubMed ID: 29924492
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma.
    Ludwig H; Strasser-Weippl K; Schreder M; Zojer N
    Ann Oncol; 2007 Jul; 18 Suppl 9():ix64-70. PubMed ID: 17631598
    [No Abstract]   [Full Text] [Related]  

  • 13. The future role of thalidomide in multiple myeloma.
    Boccadoro M; Blade J; Attal M; Palumbo A
    Acta Haematol; 2005; 114 Suppl 1():18-22. PubMed ID: 16166768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diplopia and variable ptosis as the sole initial findings in a case of orbital plasmacytoma and multiple myeloma.
    Galea M; McMillan N; Weir C
    Semin Ophthalmol; 2015 May; 30(3):235-7. PubMed ID: 24164055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thalidomide with or without dexamethasone for refractory multiple myeloma].
    Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ
    Therapie; 2002; 57(6):524-9. PubMed ID: 12666259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
    Fukushima T; Nakamura T; Iwao H; Umehara H
    Am J Hematol; 2011 Oct; 86(10):893. PubMed ID: 21812018
    [No Abstract]   [Full Text] [Related]  

  • 17. Hematology: Is thalidomide combination a new option for myeloma?
    Palumbo A
    Nat Rev Clin Oncol; 2010 Aug; 7(8):425-6. PubMed ID: 20668477
    [No Abstract]   [Full Text] [Related]  

  • 18. Analysis of durability of response to thalidomide treatment for relapsed myeloma patients.
    Myers B; Dolan G
    Br J Haematol; 2002 Jul; 118(1):347. PubMed ID: 12100175
    [No Abstract]   [Full Text] [Related]  

  • 19. Thalidomide and low-dose dexamethasone in myeloma treatment.
    Myers B; Grimley C; Dolan G
    Br J Haematol; 2001 Jul; 114(1):245. PubMed ID: 11472379
    [No Abstract]   [Full Text] [Related]  

  • 20. Isolated extraocular muscle infiltration with plasmacytoma treated with localized injection of dexamethasone.
    Painter SL; Dickens E; Elston JS
    J Neuroophthalmol; 2015 Jun; 35(2):168-70. PubMed ID: 25742058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.